{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"35"},{"groupId":"OG001","value":"31"}],"units":"Participants"}],"description":"Number of patients with any new evidence of cancer after achieving a complete response (at 12 weeks after completing chemoradiotherapy) are considered to have recurrent disease.","groups":[{"description":"Patients undergo full-dose radiotherapy once or twice daily 5 days a week for up to 7 weeks and receive cisplatin IV over 1 hour on days 1, 22, and 43 of radiotherapy.","id":"OG000","title":"Arm A"},{"description":"Patients undergo radiotherapy as in arm I and receive fluorouracil IV and cisplatin IV continuously on days 1-4 and 22-25 of radiotherapy.","id":"OG001","title":"Arm B"}],"paramType":"NUMBER","populationDescription":"Patients that had a complete response after 12 weeks of therapy","reportingStatus":"POSTED","timeFrame":"2 years after start of study","title":"Disease Recurrence","type":"SECONDARY","unitOfMeasure":"participants"}